The antiphospholipid syndrome is a bioclinical entity defined by thrombosis and/or obstetrical complications in the presence, at least 12 weeks apart, of antiphospholipid antibodies detected by coagulation test (lupus anticoagulant) or immunological assays (anticardiolipin, anti-β2-glycoprotein I antibodies). Biological markers' improvement such as anti-phosphatidylserine/prothrombin and biological score should allow better patients' management and preventive therapeutic for thrombosis and obstetrical complications. This review describes different types of antibodies, link between biological profile and risk level of thrombosis events/obstetrical complications and gives practical advice to interpret biological results.
Keywords: Anti-β2-glycoprotein I antibodies; Anticardiolipin antibodies; Anticorps anti-β2-glycoprotéine I; Anticorps anticardiolipine; Anticorps antiphospholipides; Antiphospholipid antibodies; Antiphospholipid syndrome; Lupus anticoagulant; Syndrome des antiphospholipides.
Copyright © 2017 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier SAS. All rights reserved.